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associated with stromal and vascular
calcification, report of two cases
Nephrogenic systemic fibrosis (NSF) is a systemic fibrosing disorder
characterized by the development of large indurated plaques on the
skin, primarily in patients with end-stage renal disease (ESRD). Skin
biopsy reveals an increased frequency of CD341 and Factor XIIa1
cells. Microscopic calcification has been reported in the skin biopsies of
rare cases of NSF. The etiology and significance of this calcification is
not clear. We present two cases of typical NSF, for which marked
stromal and vascular calcification was identified on skin biopsy. In both
cases, the calcification was within typical NSF lesions and was
intimately associated with aggregates of CD341, Factor XIIIa1
spindle and stellate cells. This particular pattern of calcification
strongly argues against either nonspecific dystrophic calcification or
coincidental metastatic calcification. These findings suggest that
calcification may be intrinsic to the pathophysiology of NSF, at least in
a subset of NSF patients. In addition, the vascular calcification
involving small arteries and arterioles in these two cases
morphologically resembled calciphylaxis, which is another poorly
understood complication of ESRD. This resemblance raises the
possibility that NSF may predispose to or develop in the vicinity of
indolent lesions of early-stage calciphylaxis. We propose that skin
biopsies performed as part of a diagnostic workup for suspected NSF
should preferably include the deep dermis and subcutis, in order to
assess possible vascular calcification.
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Nephrogenic systemic fibrosis (NSF), also known as
nephrogenic fibrosing dermopathy, is a systemic
fibrosing disorder primarily affecting patients with
end-stage renal disease (ESRD). Patients develop
progressive, often disabling, indurated plaques and
confluent papules on their skin.1 Although NSF has
been linked to gadolinium, its etiology is not fully
established. Calciphylaxis is another poorly under-
stood complication of ESRD, characterized by
calcification of small dermal and subcutaneous
arteries, skin ulceration and necrosis. Because both
NSF and calciphylaxis are rapidly progressive skin
conditions with potentially catastrophic outcomes,
careful differential diagnosis and timely treatment are
important.2
Microscopic calcifications are occasionally seen in
the skin biopsies of patients with NSF. The etiology
and significance of this finding remain under debate.
Some authors think that it is a non-specific dystrophic
calcification, occurring in older lesions, and is not
intrinsic to NSF,3 while others suggest that it occurs in
only a subset of NSF patients and indicates a poorer
prognosis.4 Moreover, as NSF patients often have
impaired calcium metabolism because of accompa-
nying ESRD, any calcific lesion must raise the
possibility of coincidental metastatic calcification.
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Here, we present two cases of NSF, for which
the typical skin lesions were intimately associated
with marked stromal and vascular calcification. This
particular distribution pattern makes it unlikely
that the calcific lesions can be attributed to either
non-specific dystrophic calcification or metastatic
calcification. Our cases raise the possibility that, in
certain patients, calcification may contribute to the
pathophysiology of NSF. Alternatively, as hinted by
a recent study, pre-existing calcium deposition may
facilitate the toxicity of gadolinium and predispose
to the development of NSF.5 In view of this potential
etiologic association as well as the significant morbid-
ity associated with vascular calcification, a deep skin
biopsy, including the deep dermis and subcutis, may
be preferred as part of the diagnostic evaluation in
patients suspected of having NSF.
Case 1
A 65-year-old African American woman, with a
history of hypertension, diabetes mellitus and ESRD,
had been maintained on hemodialysis for 8 years.
Her course was notable for repeated thrombotic
events, involving upper extremity catheters and the
infrarenal inferior vena cava. Her recurrent throm-
bosis had been attributed to hyperhomocysteinemia
(30.0 mmol/l, normal range 4.5–13.0) and elevated
IgA anti-beta-2 glycoprotein I (anti-b2GPI) antibodies
(35.8 and 22.6 standard international units [SAU]/ml,
performed twice, 8 weeks apart, normal , 20). She
presented with thrombosis of her translumbar dialysis
catheter, despite adequate anticoagulation, and pain in
both her arms. Physical examination was notable for
multiple areas of mildly hyperpigmented, thickened,
indurated skin, located symmetrically on her hands,
mid to upper arms, ankles andmid-abdomen.Her face
and upper trunk were spared. She had limited range of
motion about her elbows, wrists and knees. Anti-
nuclear antibody, anti-topoisomerase antibody (anti-
Scl-70), anti-b2GPI antibodies and anti-cardiolipin
antibodies were not detected during this admission.
There was no known gadolinium exposure prior to the
onset of her skin disease. Since beginning dialysis, her
serum calcium had always been within the normal
range, whereas her inorganic phosphate had been
mostly elevated, ranging from 4.2 to 9.0 mg/dl.
A skin biopsy of a lower leg lesion showed pro-
minent dermal and subcutaneous fibrosis, increased
CD341, Factor XIIIa1 spindle and dendritic cells
and increased mucin deposition (colloidal iron stain),
characteristic of NSF. In addition, there was marked
dermal stromal calcification as well as deep dermal
and subcutaneous vascular calcification (von Kossa
stain), resembling calciphylaxis. The patient sub-
sequently developed multiple comorbidities, includ-
ing severe hypotension, ischemic necrosis of the right
hand and rapid declination of mental status. Death
occurred 1 month after presentation.
Case 2
A 39-year-old Caucasian woman, with a history of
type I diabetes mellitus and ESRD, had been
maintained on hemodialysis for 7 years, following
renal allograft failure from a kidney-pancreas trans-
plant in 1999. She initially noticed somemild swelling
of lower legs in September 2005. In February 2006,
she was hospitalized for intestinal bleeding, which was
caused by a pancreatic-intestinal fistula. Three weeks
later, she developed progressive thickening and
induration of the skin on her feet, lower legs, upper
arms, hands and lower back (Fig. 1). These caused
severe limitation in the range of motion about her




knees and ankles, and she eventually became
wheelchair bound. At the same time, firm nodules
developed on her palms, interfering with her hand
function. There was no known gadolinium exposure
prior to the onset of her skin disease. Over the
preceding year, her serum calcium had been mostly
normal, ranging from 9.4 to 11.0 mg/dl, whereas
her inorganic phosphate was slightly elevated to
5.0 mg/dl.
Skin biopsy of a lower leg lesion showed thick
collagen bundles, increased stromal mucin (colloidal
iron stain) and increased spindle and stellate cells that
were positive for CD34 and Factor XIIIa. A diagnosis
of NSF was made. She was started on mycophenolate
mofetil. Excision of palmar nodules was also perfor-
med and too revealed characteristic NSF histopathol-
ogy, with increased CD341 and Factor XIIIa1 cells.
Stromal calcification, as well as vascular calcification
involving small deep dermal and subcutaneous
arteries, was present in all specimens (Fig. 2).
Calcification was intimately associated with aggre-
gates of spindle and stellate cells. Stromal calcification
was particularly prominent in the palmar nodules and
resembled calcinosis. The patient was treated with
mycophenolate mofetil, intravenous immunoglobulin
(IVIG) and rituximab for her disabling skin disease.
The skin stiffness and thickening improved markedly.
The patient is currently alive and well.
Discussion
Cowper et al.1 first described NSF in 2000 as
a scleromyxedema-like disease in 15 dialysis patients,
who developed diffuse thickening and induration of
their skin, with histology showing increased fibro-
blast-like dermal cells associated with collagen
remodeling and mucin deposition. Although the
etiology of NSF is still unclear, an association with
gadolinium, a component of magnetic resonance
imaging (MRI) contrast agents, has been suggested by
multiple studies.6 However, both of our cases lacked
a clear history of gadolinium exposure. Currently,
there is no established treatment for NSF.
Calcification is an uncommon finding in NSF
biopsies. Although it has been observed in several
cases, there is no consensus on its etiology or
significance. Cowper et al.3 suggested that such
calcification may be non-specific and dystrophic in
nature. In contrast, Edsall et al.4 reported two cases of
NSF with extensive stromal calcium deposition,
which they believed was a manifestation of metastatic
calcification. The biopsy of one patient also showed
calciphylaxis-like vascular calcification. They also
suggested that both calcification and fibrosis may be
related to the activity of transforming growth factor-
b/Smad signaling pathway. Ting et al.7 reported the
autopsy of a NSF patient that revealed extensive
fibrosis and stromal calcification in the dermis and
skeletal muscle, as well as vascular calcification in
multiple internal organs. Hershko et al. reported two
cases of NSF with osteoclast-like giant cells and
suggested that these cases may represent a variant of
NSF. One of these patients had stromal and vascular
calcification morphologically similar to our cases.8
Swartz et al.9 noted focal dermal calcification in 1 of
13 NSF patients, but further details were not
Fig. 2. A) Biopsy of palmar lesion shows
increased fibroblast-like cells and marked
stromal calcification (325). B) Small sub-
cutaneous arteries with marked medial
calcification (3100). Inset shows von Kossa
stain. C) CD34 immunohistochemical stain




published. Markus et al.10 reported subcutaneous
stromal calcification in two of four NSF patients.
Finally, Lewis et al.11 reported one case with clinically
and histologically overlapping NSFand calciphylaxis.
Our cases may provide insight into the role of
calcification in NSF. In both cases, calcification was
intimately associated with aggregates of CD341 and
Factor XIIIa1 spindle and stellate cells, often tightly
surrounded by these cells. It should be noted that
calcified lesions are not uncommon in dialysis patients
as a result of metastatic calcification. However, the
anatomic proximity observed in our cases argues
against the possibility of coincidental metastatic
calcification. Non-specific dystrophic calcification
seems equally unlikely because it is supposed to be
limited to the stroma, and both of our patients had
vascular calcifications. We hypothesize that in certain
patients withNSF, calcificationmay be intrinsic to the
disease process.
A recent report by Boyd et al. suggests a patho-
physiologic mechanism for this association. In their
report, gadolinium was detected in dermal vessel
walls, but only in areas with concomitant calcium
phosphate deposition.5 Because gadolinium is toxic
only in its free form, whereas gadolinium-based MRI
contrast agents contain exclusively chelated gadoli-
nium, toxicity requires that free gadolinium somehow
be released into tissues. Calcium phosphate particles
may provide a mechanism for the release of free
gadolinium by a transmetallation reaction, and
thereby serve as a precipitating factor for NSF.
There may be an additional significance to the
vascular calcification seen in our two cases. Calcifi-
cation of subcutaneous blood vessels, including small
arteries and arterioles, is the pathological hallmark of
calciphylaxis. Such vascular calcification may be
accompanied by intimal hyperplasia and thrombosis,
leading to ischemia, skin ulceration and necrosis.12
The morphological resemblance to calciphylaxis in
our two cases raises the possibility that NSF may
predispose to or harbor indolent lesions characteristic
of an early stage of calciphylaxis. Cases with co-
existing NSF and calciphylaxis have been reported in
the literature.11 In view of this potential association,
a deep skin biopsy reaching the subcutis may be
indicated in patients with suspected NSF.
NSF, rather than being a coincidence, may offer
insight into the pathophysiology of this puzzling
syndrome. Future studies should examine the validity
of our observation because a greater understanding of
the role of calcification in NSF may lead to new
strategies for both treatment and prevention.
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In summary, we present two cases of NSF with
concomitant stromal and vascular calcification. We
hypothesize that the association of calcification with
